In many cases, a pharmacy's most valuable asset is its NHS contract. This is what buyers are paying for - the right to provide pharmaceutical services
commissioned by the NHS and be reimbursed for the medicines dispensed.
However, a pharmacy consists of more than just an NHS contract and when buyers look for a pharmacy to buy, they will also examine these other areas - the pharmacy's
customer base, its staff, the property it operates from - to name a few - because these are all also crucial to a successful pharmacy.
In this day and age, another important consideration is the pharmacy's intellectual property (IP) i.e. the pharmacy's rights to certain types of information, ideas,
and forms of expression. At the most basic level, this includes the trade mark in the name of the pharmacy, because all pharmacies will have a name by which they
distinguish themselves from other pharmacies. The more well-known the name, the more valuable this form of IP is - mention 'Boots', for example, and most will have
an instant association with the largest pharmaceutical retailer in the UK.
An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights
for Covid-19 interventions between the pharmaceutical industry and developing nations endures.
At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries
when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected.
In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry
collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA).
The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved
in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck.
The declaration is not legally binding.
However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.